Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 18/20 | 0.71 |
| ▸ | DYRK1B | Q9Y463 | 12/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | KIF5B | P33176 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14733505 | 0.91 | DYRK1A (0.68) | DYRK1ADYRK1BGSK3AGSK3B | |
| SCHEMBL14733586 | 0.85 | DYRK1A (0.68) | DYRK1ADYRK1B | |
| SCHEMBL14733498 | 0.84 | DYRK1A (0.72) | DYRK1ADYRK1BGSK3AGSK3B | |
| SCHEMBL14733446 | 0.83 | DYRK1A (1.00) | DYRK1ADYRK1BGSK3AGSK3B | |
| SCHEMBL14733487 | 0.83 | DYRK1A (0.67) | DYRK1ADYRK1BGSK3AGSK3B | |
| SCHEMBL14733423 | 0.82 | DYRK1A (0.66) | DYRK1ADYRK1BGSK3AGSK3B | |
| SCHEMBL17060625 | 0.82 | DYRK1A (0.87) | DYRK1ADYRK1BGSK3AGSK3B | |
| SCHEMBL14733497 | 0.82 | DYRK1A (0.67) | DYRK1ADYRK1BGSK3AGSK3B | |
| SCHEMBL14733587 | 0.82 | DYRK1A (0.62) | DYRK1ADYRK1BGSK3AGSK3B | |
| SCHEMBL14733529 | 0.80 | DYRK1A (0.62) | DYRK1ADYRK1BRAF1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | disclosed |
| US-9446044-B2 | DYRK1 inhibitors and uses thereof | DIAXONHIT (FR) | 2016-09-20 | — | — | US | disclosed |
| EP-2744797-B1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | disclosed |
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DIAXONHIT (FR) | 2014-09-18 | — | — | US | disclosed |
| WO-2013026806-A1 | DYRK1 INHIBITORS AND USES THEREOF | EXONHIT SA (FR) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275064-A1 | DYRK1 INHIBITORS AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | DYRK1A 1/4885DYRK1B 2/4885RET 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.